Clinical Research Directory
Browse clinical research sites, groups, and studies.
Adjuvant Anti-PD-1 Therapy in Resected Hepatocellular Carcinoma
Sponsor: Tongji Hospital
Summary
Early hepatocellular carcinoma (HCC) recurrence (driven by residual tumors) and late recurrence (driven by de novo tumors) exhibit distinct biological behaviors, suggesting differential therapeutic vulnerabilities. The beneficiaries of adjuvant PD-1 inhibitors (aPD-1) and their efficacy across these temporally divergent recurrence patterns remains unestablished.
Official title: Efficacy of Postoperative Adjuvant PD-1 Inhibitors Guided by a Deep Learning Model: a Multicenter, Prospective Cohort Study
Key Details
Gender
All
Age Range
18 Years - 75 Years
Study Type
OBSERVATIONAL
Enrollment
300
Start Date
2026-01-31
Completion Date
2031-12-31
Last Updated
2026-01-30
Healthy Volunteers
Not specified
Interventions
PD-1 Inhibitors
Patients in the adjuvant cohort received at least one cycle of PD-1 inhibitors.